Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
about
Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.Passive blood anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction.Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland.Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
P2860
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy, safety, tolerability ...... th primary immunodeficiencies.
@en
Efficacy, safety, tolerability ...... th primary immunodeficiencies.
@nl
type
label
Efficacy, safety, tolerability ...... th primary immunodeficiencies.
@en
Efficacy, safety, tolerability ...... th primary immunodeficiencies.
@nl
prefLabel
Efficacy, safety, tolerability ...... th primary immunodeficiencies.
@en
Efficacy, safety, tolerability ...... th primary immunodeficiencies.
@nl
P2093
P2860
P356
P1476
Efficacy, safety, tolerability ...... th primary immunodeficiencies.
@en
P2093
B Derfalvi
C Bourgeois
P2860
P304
P356
10.1111/CEI.12866
P577
2016-09-10T00:00:00Z